- Home
- PTY vs AKRO Comparison
PTY vs AKRO Comparison
Compare PTY & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTY
- AKRO
- Stock Information
- Founded
- PTY 2002
- AKRO 2017
- Country
- PTY United States
- AKRO United States
- Employees
- PTY N/A
- AKRO N/A
- Industry
- PTY Investment Managers
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- PTY Finance
- AKRO Health Care
- Exchange
- PTY Nasdaq
- AKRO Nasdaq
- Market Cap
- PTY 2.2B
- AKRO 2.0B
- IPO Year
- PTY N/A
- AKRO 2019
- Fundamental
- Price
- PTY $14.49
- AKRO $25.60
- Analyst Decision
- PTY
- AKRO Strong Buy
- Analyst Count
- PTY 0
- AKRO 8
- Target Price
- PTY N/A
- AKRO $46.83
- AVG Volume (30 Days)
- PTY 550.4K
- AKRO 842.7K
- Earning Date
- PTY 01-01-0001
- AKRO 02-27-2025
- Dividend Yield
- PTY 9.65%
- AKRO N/A
- EPS Growth
- PTY N/A
- AKRO N/A
- EPS
- PTY N/A
- AKRO N/A
- Revenue
- PTY N/A
- AKRO N/A
- Revenue This Year
- PTY N/A
- AKRO N/A
- Revenue Next Year
- PTY N/A
- AKRO N/A
- P/E Ratio
- PTY N/A
- AKRO N/A
- Revenue Growth
- PTY N/A
- AKRO N/A
- 52 Week Low
- PTY $11.92
- AKRO $15.32
- 52 Week High
- PTY $14.88
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- PTY 56.06
- AKRO 44.22
- Support Level
- PTY $14.35
- AKRO $21.34
- Resistance Level
- PTY $14.45
- AKRO $28.94
- Average True Range (ATR)
- PTY 0.09
- AKRO 1.35
- MACD
- PTY 0.02
- AKRO -0.09
- Stochastic Oscillator
- PTY 97.27
- AKRO 56.05
About PTY Pimco Corporate & Income Opportunity Fund
PIMCO Corporate & Income Opportunity Fds operates as a closed-end management investment company. It seeks to maximize total return through a combination of current income and capital appreciation. The fund invests a majority of the total assets in a combination of corporate debt obligations of varying maturities, other corporate income-producing securities, and income-producing securities of non-corporate issuers, such as U.S. Government securities, municipal securities, and mortgage-backed and other asset-backed securities issued on a public or private basis.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.